• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Navigating treatment sequencing in ALK-positive non-small cell lung cancer: lorlatinib as a key to prolonged survival?

作者信息

Ulhøi Maiken Parm, Meldgaard Peter

机构信息

Department of Oncology, Aarhus University Hospital (AUH), Aarhus, Denmark.

出版信息

Transl Lung Cancer Res. 2025 Jul 31;14(7):2359-2363. doi: 10.21037/tlcr-2025-373. Epub 2025 Jul 28.

DOI:10.21037/tlcr-2025-373
PMID:40799441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12337053/
Abstract
摘要

相似文献

1
Navigating treatment sequencing in ALK-positive non-small cell lung cancer: lorlatinib as a key to prolonged survival?ALK 阳性非小细胞肺癌治疗顺序的抉择：洛拉替尼是延长生存期的关键吗？
Transl Lung Cancer Res. 2025 Jul 31;14(7):2359-2363. doi: 10.21037/tlcr-2025-373. Epub 2025 Jul 28.
2
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).洛拉替尼与其他间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂（TKI）作为一线治疗ALK 阳性晚期非小细胞肺癌（NSCLC）的比较：系统评价和网络荟萃分析。
Lung Cancer. 2024 Nov;197:107968. doi: 10.1016/j.lungcan.2024.107968. Epub 2024 Sep 29.
3
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.洛拉替尼用于治疗晚期间变性淋巴瘤激酶阳性非小细胞肺癌：IFCT-1803 LORLATU队列研究结果
Eur J Cancer. 2022 May;166:51-59. doi: 10.1016/j.ejca.2022.01.018. Epub 2022 Mar 9.
4
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.洛拉替尼在瑞典一线治疗间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌成人患者中的成本效益分析。
Appl Health Econ Health Policy. 2023 Jul;21(4):661-672. doi: 10.1007/s40258-023-00807-7. Epub 2023 May 12.
5
Anti-EGFR therapy can overcome acquired resistance to the third-generation ALK-tyrosine kinase inhibitor lorlatinib mediated by activation of EGFR.抗表皮生长因子受体（EGFR）疗法可克服因EGFR激活介导的对第三代间变性淋巴瘤激酶（ALK）-酪氨酸激酶抑制剂劳拉替尼的获得性耐药。
Acta Pharmacol Sin. 2025 Mar 21. doi: 10.1038/s41401-025-01511-z.
6
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.晚期间变性淋巴瘤激酶（<I>ALK</I>）重排非小细胞肺癌的靶向治疗。
Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2.
7
Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China.劳拉替尼治疗ALK阳性晚期非小细胞肺癌的疗效和安全性分析：一项中国多中心真实世界研究
BMC Cancer. 2025 Jul 25;25(1):1216. doi: 10.1186/s12885-025-14631-w.
8
Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.克唑替尼进展后不同序贯模式治疗晚期间变性淋巴瘤激酶阳性非小细胞肺癌的疗效。
Thorac Cancer. 2022 Jun;13(12):1788-1794. doi: 10.1111/1759-7714.14455. Epub 2022 May 13.
9
Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.一线治疗晚期间变性淋巴瘤激酶突变型非小细胞肺癌患者的疗效和安全性：系统评价和网络荟萃分析。
Cancer. 2023 Apr 15;129(8):1261-1275. doi: 10.1002/cncr.34664. Epub 2023 Feb 7.
10
Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.动态监测循环肿瘤 DNA 分析 ALK 阳性经治 NSCLC 患者中 lorlatinib 的遗传特征和耐药谱。
Thorac Cancer. 2023 Jul;14(20):1980-1990. doi: 10.1111/1759-7714.14980. Epub 2023 Jun 2.

本文引用的文献

1
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.关键2期研究中劳拉替尼治疗ALK阳性非小细胞肺癌患者的最终总生存期和长期安全性：简要报告
J Thorac Oncol. 2025 Apr;20(4):513-520. doi: 10.1016/j.jtho.2024.11.021. Epub 2024 Nov 22.
2
Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future care.劳拉替尼相关的体重增加和血脂异常：一项回顾性分析及对未来治疗的启示
Lung Cancer. 2024 Dec;198:108034. doi: 10.1016/j.lungcan.2024.108034. Epub 2024 Nov 19.
3
Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC.
ALK+ NSCLC 患者三线治疗的真实世界治疗模式和结局。
Adv Ther. 2024 Aug;41(8):3217-3231. doi: 10.1007/s12325-024-02899-6. Epub 2024 Jun 25.
4
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.ALK 阳性 NSCLC 二代 ALK-TKIs 时代的进展模式、耐药机制及后续治疗。
J Transl Med. 2024 Jun 20;22(1):585. doi: 10.1186/s12967-024-05388-0.
5
The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer.局部治疗在癌基因成瘾性非小细胞肺癌寡进展性疾病中的作用
Adv Radiat Oncol. 2024 Apr 14;9(7):101516. doi: 10.1016/j.adro.2024.101516. eCollection 2024 Jul.
6
Lorlatinib Versus Crizotinib in Patients With Advanced -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.洛拉替尼对比克唑替尼用于治疗晚期 ALK 阳性非小细胞肺癌患者：III 期 CROWN 研究的 5 年结果。
J Clin Oncol. 2024 Oct 10;42(29):3400-3409. doi: 10.1200/JCO.24.00581. Epub 2024 May 31.
7
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.布加替尼对比阿来替尼用于克唑替尼治疗后进展的 ALK 阳性 NSCLC ：III 期 ALTA-3 试验结果。
J Thorac Oncol. 2023 Dec;18(12):1743-1755. doi: 10.1016/j.jtho.2023.08.010. Epub 2023 Aug 12.
8
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.一线劳拉替尼对比克唑替尼治疗晚期ALK阳性非小细胞肺癌患者的疗效和安全性：3期随机开放标签CROWN研究数据的更新分析
Lancet Respir Med. 2023 Apr;11(4):354-366. doi: 10.1016/S2213-2600(22)00437-4. Epub 2022 Dec 16.
9
Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.真实世界中晚期ALK 重排非小细胞肺癌患者的治疗序贯、毒性、健康效用和生存结局。
Clin Lung Cancer. 2023 Jan;24(1):40-50. doi: 10.1016/j.cllc.2022.09.007. Epub 2022 Sep 24.
10
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory + NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.布加替尼用于克唑替尼难治性非小细胞肺癌的长期疗效与安全性：1/2期及随机2期（ALTA）试验的最终结果
JTO Clin Res Rep. 2022 Jul 31;3(9):100385. doi: 10.1016/j.jtocrr.2022.100385. eCollection 2022 Sep.